Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Seres Therapeutics Announces Vowst Preliminary Net Sales Of Approximately $10.4M (Unaudited) For Q4 Of 2023, Total 2023 Net Sales Since Launch In June Were Approximately $19.6M And Reflected A Gross-to-net Reduction Of 13%

Author: Benzinga Newsdesk | January 09, 2024 08:11am

Significant adoption of VOWST since commercial launch in June 2023 through year-end 2023 with 2,833 patient enrollment forms received and 2,015 new patient starts

Posted In: MCRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist